Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Dendritic Cell Immunotherapy for Pediatric High-grade Glioma and DIPG
NCT04911621Phase 2Completed
- Start
- Sep 2021
- Primary completion
- Aug 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of WT1 mRNA-loaded autologous monocyte-derived dendritic cells in glioma and diffuse intrinsic pontine glioma (DIPG) (2 arms). Primary endpoints: Feasibility of leukapheresis, Feasibility of WT1-targeted DC vaccine production and 5 more. Started Sep 2021; status: completed.
02
Drugs
WT1 mRNA-loaded autologous monocyte-derived dendritic cells
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT04911621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911621.